Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy Article Swipe

View

H. Josh Jang , Galen Hostetter , Alexander W. MacFarlane , Zachary Madaj , Eric A. Ross , Toshinori Hinoue , Justin R. Kulchycki , Ryan S. Burgos , Mahvish Tafseer , R. Katherine Alpaugh , Candice L. Schwebel , Rutika Kokate , Daniel M. Geynisman , Matthew R. Zibelman , Pooja Ghatalia , Peter W. Nichols , Woonbok Chung , Jozef Madžo , Noah M. Hahn , David I. Quinn , Jean‐Pierre J. Issa , Michael J. Topper , Stephen B. Baylin , Hui Shen , Kerry S. Campbell , Peter A. Jones , Elizabeth R. Plimack ·

YOU? · · 2024 · Open Access · · DOI: https://doi.org/10.1158/1078-0432.27030415.v1

Supplementary Tables Supplementary Table 1: Patient and tumor sample information Supplementary Table 2: Tumor mutation burden Supplementary Table 3: Unfiltered whole exome sequencing mutation analysis Supplementary Table 4: Filtered whole exome sequencing mutation analysis Supplementary Table 5: Immunohistochemistry scores of tumors Supplementary Table 6: FACS panel for PBMC analysis Supplementary Table 7: Geometric mean fluorescence intensity (GMFI) from PBMC FACS Supplementary Table 8: Representativeness of Study Participants

Related Topics

Atezolizumab

Transitional Cell Carcinoma

Concepts

Atezolizumab Metastatic Urothelial Carcinoma Oncology Medicine Cancer research Internal medicine Immunotherapy Urothelial carcinoma Bladder cancer Cancer Pembrolizumab

Metadata

Type: supplementary-materials
Language: en
Landing Page: https://doi.org/10.1158/1078-0432.27030415.v1
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4402818807

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4402818807

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/1078-0432.27030415.v1

Digital Object Identifier
Title: Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

Work title
Type: supplementary-materials

OpenAlex work type
Language: en

Primary language
Publication year: 2024

Year of publication
Publication date: 2024-09-16

Full publication date if available
Authors: H. Josh Jang, Galen Hostetter, Alexander W. MacFarlane, Zachary Madaj, Eric A. Ross, Toshinori Hinoue, Justin R. Kulchycki, Ryan S. Burgos, Mahvish Tafseer, R. Katherine Alpaugh, Candice L. Schwebel, Rutika Kokate, Daniel M. Geynisman, Matthew R. Zibelman, Pooja Ghatalia, Peter W. Nichols, Woonbok Chung, Jozef Madžo, Noah M. Hahn, David I. Quinn, Jean‐Pierre J. Issa, Michael J. Topper, Stephen B. Baylin, Hui Shen, Kerry S. Campbell, Peter A. Jones, Elizabeth R. Plimack

List of authors in order
Landing page: https://doi.org/10.1158/1078-0432.27030415.v1

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://doi.org/10.1158/1078-0432.27030415.v1

Direct OA link when available
Concepts: Atezolizumab, Metastatic Urothelial Carcinoma, Oncology, Medicine, Cancer research, Internal medicine, Immunotherapy, Urothelial carcinoma, Bladder cancer, Cancer, Pembrolizumab

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4402818807
doi	https://doi.org/10.1158/1078-0432.27030415.v1
ids.doi	https://doi.org/10.1158/1078-0432.27030415.v1
ids.openalex	https://openalex.org/W4402818807
fwci
type	supplementary-materials
title	Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T10458
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9994999766349792
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2746
topics[0].subfield.display_name	Surgery
topics[0].display_name	Bladder and Urothelial Cancer Treatments
topics[1].id	https://openalex.org/T10158
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9990000128746033
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2730
topics[1].subfield.display_name	Oncology
topics[1].display_name	Cancer Immunotherapy and Biomarkers
topics[2].id	https://openalex.org/T12695
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9787999987602234
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2746
topics[2].subfield.display_name	Surgery
topics[2].display_name	Urinary and Genital Oncology Studies
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2775949291
concepts[0].level	5
concepts[0].score	0.9568278789520264
concepts[0].wikidata	https://www.wikidata.org/wiki/Q20707748
concepts[0].display_name	Atezolizumab
concepts[1].id	https://openalex.org/C2911057145
concepts[1].level	5
concepts[1].score	0.7102826237678528
concepts[1].wikidata	https://www.wikidata.org/wiki/Q2501186
concepts[1].display_name	Metastatic Urothelial Carcinoma
concepts[2].id	https://openalex.org/C143998085
concepts[2].level	1
concepts[2].score	0.553471565246582
concepts[2].wikidata	https://www.wikidata.org/wiki/Q162555
concepts[2].display_name	Oncology
concepts[3].id	https://openalex.org/C71924100
concepts[3].level	0
concepts[3].score	0.4851303994655609
concepts[3].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[3].display_name	Medicine
concepts[4].id	https://openalex.org/C502942594
concepts[4].level	1
concepts[4].score	0.4715298116207123
concepts[4].wikidata	https://www.wikidata.org/wiki/Q3421914
concepts[4].display_name	Cancer research
concepts[5].id	https://openalex.org/C126322002
concepts[5].level	1
concepts[5].score	0.42307227849960327
concepts[5].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[5].display_name	Internal medicine
concepts[6].id	https://openalex.org/C2777701055
concepts[6].level	3
concepts[6].score	0.3609495759010315
concepts[6].wikidata	https://www.wikidata.org/wiki/Q1427096
concepts[6].display_name	Immunotherapy
concepts[7].id	https://openalex.org/C3019882237
concepts[7].level	4
concepts[7].score	0.33193767070770264
concepts[7].wikidata	https://www.wikidata.org/wiki/Q2501186
concepts[7].display_name	Urothelial carcinoma
concepts[8].id	https://openalex.org/C2780352672
concepts[8].level	3
concepts[8].score	0.23956331610679626
concepts[8].wikidata	https://www.wikidata.org/wiki/Q504775
concepts[8].display_name	Bladder cancer
concepts[9].id	https://openalex.org/C121608353
concepts[9].level	2
concepts[9].score	0.2049887776374817
concepts[9].wikidata	https://www.wikidata.org/wiki/Q12078
concepts[9].display_name	Cancer
concepts[10].id	https://openalex.org/C2780057760
concepts[10].level	4
concepts[10].score	0.1950669288635254
concepts[10].wikidata	https://www.wikidata.org/wiki/Q13896859
concepts[10].display_name	Pembrolizumab
keywords[0].id	https://openalex.org/keywords/atezolizumab
keywords[0].score	0.9568278789520264
keywords[0].display_name	Atezolizumab
keywords[1].id	https://openalex.org/keywords/metastatic-urothelial-carcinoma
keywords[1].score	0.7102826237678528
keywords[1].display_name	Metastatic Urothelial Carcinoma
keywords[2].id	https://openalex.org/keywords/oncology
keywords[2].score	0.553471565246582
keywords[2].display_name	Oncology
keywords[3].id	https://openalex.org/keywords/medicine
keywords[3].score	0.4851303994655609
keywords[3].display_name	Medicine
keywords[4].id	https://openalex.org/keywords/cancer-research
keywords[4].score	0.4715298116207123
keywords[4].display_name	Cancer research
keywords[5].id	https://openalex.org/keywords/internal-medicine
keywords[5].score	0.42307227849960327
keywords[5].display_name	Internal medicine
keywords[6].id	https://openalex.org/keywords/immunotherapy
keywords[6].score	0.3609495759010315
keywords[6].display_name	Immunotherapy
keywords[7].id	https://openalex.org/keywords/urothelial-carcinoma
keywords[7].score	0.33193767070770264
keywords[7].display_name	Urothelial carcinoma
keywords[8].id	https://openalex.org/keywords/bladder-cancer
keywords[8].score	0.23956331610679626
keywords[8].display_name	Bladder cancer
keywords[9].id	https://openalex.org/keywords/cancer
keywords[9].score	0.2049887776374817
keywords[9].display_name	Cancer
keywords[10].id	https://openalex.org/keywords/pembrolizumab
keywords[10].score	0.1950669288635254
keywords[10].display_name	Pembrolizumab
language	en
locations[0].id	doi:10.1158/1078-0432.27030415.v1
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/1078-0432.27030415.v1
locations[1].id	pmh:oai:figshare.com:article/27030415
locations[1].is_oa	True
locations[1].source.id	https://openalex.org/S4306400572
locations[1].source.issn
locations[1].source.type	repository
locations[1].source.is_oa	False
locations[1].source.issn_l
locations[1].source.is_core	False
locations[1].source.is_in_doaj	False
locations[1].source.display_name	OPAL (Open@LaTrobe) (La Trobe University)
locations[1].source.host_organization	https://openalex.org/I196829312
locations[1].source.host_organization_name	La Trobe University
locations[1].source.host_organization_lineage	https://openalex.org/I196829312
locations[1].license	cc-by
locations[1].pdf_url
locations[1].version	submittedVersion
locations[1].raw_type	Dataset
locations[1].license_id	https://openalex.org/licenses/cc-by
locations[1].is_accepted	False
locations[1].is_published	False
locations[1].raw_source_name
locations[1].landing_page_url	https://figshare.com/articles/dataset/Supplementary_Tables_1_from_A_Phase_II_Trial_of_Guadecitabine_plus_Atezolizumab_in_Metastatic_Urothelial_Carcinoma_Progressing_after_Initial_Immune_Checkpoint_Inhibitor_Therapy/27030415
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5018798845
authorships[0].author.orcid	https://orcid.org/0000-0001-9654-4448
authorships[0].author.display_name	H. Josh Jang
authorships[0].author_position	first
authorships[0].raw_author_name	H. Josh Jang
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5062941900
authorships[1].author.orcid	https://orcid.org/0000-0003-2616-6861
authorships[1].author.display_name	Galen Hostetter
authorships[1].author_position	middle
authorships[1].raw_author_name	Galen Hostetter
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5079510865
authorships[2].author.orcid	https://orcid.org/0000-0003-1740-4848
authorships[2].author.display_name	Alexander W. MacFarlane
authorships[2].author_position	middle
authorships[2].raw_author_name	Alexander W. MacFarlane
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5026553060
authorships[3].author.orcid	https://orcid.org/0000-0003-2330-0500
authorships[3].author.display_name	Zachary Madaj
authorships[3].author_position	middle
authorships[3].raw_author_name	Zachary Madaj
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5048218662
authorships[4].author.orcid	https://orcid.org/0000-0002-0890-2418
authorships[4].author.display_name	Eric A. Ross
authorships[4].author_position	middle
authorships[4].raw_author_name	Eric A. Ross
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5026537645
authorships[5].author.orcid	https://orcid.org/0000-0002-5078-5016
authorships[5].author.display_name	Toshinori Hinoue
authorships[5].author_position	middle
authorships[5].raw_author_name	Toshinori Hinoue
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5005720140
authorships[6].author.orcid	https://orcid.org/0000-0002-4000-9320
authorships[6].author.display_name	Justin R. Kulchycki
authorships[6].author_position	middle
authorships[6].raw_author_name	Justin R. Kulchycki
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5008135649
authorships[7].author.orcid	https://orcid.org/0000-0002-3683-6286
authorships[7].author.display_name	Ryan S. Burgos
authorships[7].author_position	middle
authorships[7].raw_author_name	Ryan S. Burgos
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5024888036
authorships[8].author.orcid	https://orcid.org/0000-0002-6425-8292
authorships[8].author.display_name	Mahvish Tafseer
authorships[8].author_position	middle
authorships[8].raw_author_name	Mahvish Tafseer
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5049901305
authorships[9].author.orcid	https://orcid.org/0000-0002-6775-5323
authorships[9].author.display_name	R. Katherine Alpaugh
authorships[9].author_position	middle
authorships[9].raw_author_name	R. Katherine Alpaugh
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5083779488
authorships[10].author.orcid	https://orcid.org/0000-0002-2788-3486
authorships[10].author.display_name	Candice L. Schwebel
authorships[10].author_position	middle
authorships[10].raw_author_name	Candice L. Schwebel
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5033555611
authorships[11].author.orcid	https://orcid.org/0000-0002-2932-3570
authorships[11].author.display_name	Rutika Kokate
authorships[11].author_position	middle
authorships[11].raw_author_name	Rutika Kokate
authorships[11].is_corresponding	False
authorships[12].author.id	https://openalex.org/A5033372450
authorships[12].author.orcid	https://orcid.org/0000-0002-1423-5295
authorships[12].author.display_name	Daniel M. Geynisman
authorships[12].author_position	middle
authorships[12].raw_author_name	Daniel M. Geynisman
authorships[12].is_corresponding	False
authorships[13].author.id	https://openalex.org/A5051789976
authorships[13].author.orcid	https://orcid.org/0000-0003-1475-6477
authorships[13].author.display_name	Matthew R. Zibelman
authorships[13].author_position	middle
authorships[13].raw_author_name	Matthew R. Zibelman
authorships[13].is_corresponding	False
authorships[14].author.id	https://openalex.org/A5079166812
authorships[14].author.orcid	https://orcid.org/0000-0001-6229-7581
authorships[14].author.display_name	Pooja Ghatalia
authorships[14].author_position	middle
authorships[14].raw_author_name	Pooja Ghatalia
authorships[14].is_corresponding	False
authorships[15].author.id	https://openalex.org/A5001296274
authorships[15].author.orcid	https://orcid.org/0000-0003-4030-5493
authorships[15].author.display_name	Peter W. Nichols
authorships[15].author_position	middle
authorships[15].raw_author_name	Peter W. Nichols
authorships[15].is_corresponding	False
authorships[16].author.id	https://openalex.org/A5079853830
authorships[16].author.orcid	https://orcid.org/0000-0002-3663-8554
authorships[16].author.display_name	Woonbok Chung
authorships[16].author_position	middle
authorships[16].raw_author_name	Woonbok Chung
authorships[16].is_corresponding	False
authorships[17].author.id	https://openalex.org/A5014780308
authorships[17].author.orcid	https://orcid.org/0000-0001-6607-1213
authorships[17].author.display_name	Jozef Madžo
authorships[17].author_position	middle
authorships[17].raw_author_name	Jozef Madzo
authorships[17].is_corresponding	False
authorships[18].author.id	https://openalex.org/A5001308517
authorships[18].author.orcid	https://orcid.org/0000-0002-1016-9024
authorships[18].author.display_name	Noah M. Hahn
authorships[18].author_position	middle
authorships[18].raw_author_name	Noah M. Hahn
authorships[18].is_corresponding	False
authorships[19].author.id	https://openalex.org/A5031088617
authorships[19].author.orcid	https://orcid.org/0000-0002-1411-0417
authorships[19].author.display_name	David I. Quinn
authorships[19].author_position	middle
authorships[19].raw_author_name	David I. Quinn
authorships[19].is_corresponding	False
authorships[20].author.id	https://openalex.org/A5062330946
authorships[20].author.orcid	https://orcid.org/0000-0003-2258-5030
authorships[20].author.display_name	Jean‐Pierre J. Issa
authorships[20].author_position	middle
authorships[20].raw_author_name	Jean-Pierre J. Issa
authorships[20].is_corresponding	False
authorships[21].author.id	https://openalex.org/A5059640571
authorships[21].author.orcid	https://orcid.org/0000-0002-2778-4920
authorships[21].author.display_name	Michael J. Topper
authorships[21].author_position	middle
authorships[21].raw_author_name	Michael J. Topper
authorships[21].is_corresponding	False
authorships[22].author.id	https://openalex.org/A5058612163
authorships[22].author.orcid	https://orcid.org/0000-0003-3697-3798
authorships[22].author.display_name	Stephen B. Baylin
authorships[22].author_position	middle
authorships[22].raw_author_name	Stephen B. Baylin
authorships[22].is_corresponding	False
authorships[23].author.id	https://openalex.org/A5015458809
authorships[23].author.orcid	https://orcid.org/0000-0001-9767-4084
authorships[23].author.display_name	Hui Shen
authorships[23].author_position	middle
authorships[23].raw_author_name	Hui Shen
authorships[23].is_corresponding	False
authorships[24].author.id	https://openalex.org/A5036296799
authorships[24].author.orcid	https://orcid.org/0000-0003-4665-7326
authorships[24].author.display_name	Kerry S. Campbell
authorships[24].author_position	middle
authorships[24].raw_author_name	Kerry S. Campbell
authorships[24].is_corresponding	False
authorships[25].author.id	https://openalex.org/A5088347458
authorships[25].author.orcid	https://orcid.org/0000-0001-8309-4767
authorships[25].author.display_name	Peter A. Jones
authorships[25].author_position	middle
authorships[25].raw_author_name	Peter A. Jones
authorships[25].is_corresponding	False
authorships[26].author.id	https://openalex.org/A5032422193
authorships[26].author.orcid	https://orcid.org/0000-0002-7618-0744
authorships[26].author.display_name	Elizabeth R. Plimack
authorships[26].author_position	last
authorships[26].raw_author_name	Elizabeth R. Plimack
authorships[26].is_corresponding	False
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://doi.org/10.1158/1078-0432.27030415.v1
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T10458
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9994999766349792
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2746
primary_topic.subfield.display_name	Surgery
primary_topic.display_name	Bladder and Urothelial Cancer Treatments
related_works	https://openalex.org/W2775971156, https://openalex.org/W4212927231, https://openalex.org/W4250109026, https://openalex.org/W2322982550, https://openalex.org/W4237724415, https://openalex.org/W2763688581, https://openalex.org/W4389606373, https://openalex.org/W4246023460, https://openalex.org/W2470163336, https://openalex.org/W4388134105
cited_by_count	0
locations_count	2
best_oa_location.id	doi:10.1158/1078-0432.27030415.v1
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/1078-0432.27030415.v1
primary_location.id	doi:10.1158/1078-0432.27030415.v1
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/1078-0432.27030415.v1
publication_date	2024-09-16
publication_year	2024
referenced_works_count	0
abstract_inverted_index.1:	4
abstract_inverted_index.2:	12
abstract_inverted_index.3:	18
abstract_inverted_index.4:	27
abstract_inverted_index.5:	36
abstract_inverted_index.6:	43
abstract_inverted_index.7:	51
abstract_inverted_index.8:	62
abstract_inverted_index.of	39, 64
abstract_inverted_index.and	6
abstract_inverted_index.for	46
abstract_inverted_index.FACS	44, 59
abstract_inverted_index.PBMC	47, 58
abstract_inverted_index.from	57
abstract_inverted_index.mean	53
abstract_inverted_index.Study	65
abstract_inverted_index.Table	3, 11, 17, 26, 35, 42, 50, 61
abstract_inverted_index.Tumor	13
abstract_inverted_index.exome	21, 30
abstract_inverted_index.panel	45
abstract_inverted_index.tumor	7
abstract_inverted_index.whole	20, 29
abstract_inverted_index.(GMFI)	56
abstract_inverted_index.Tables	1
abstract_inverted_index.burden	15
abstract_inverted_index.sample	8
abstract_inverted_index.scores	38
abstract_inverted_index.tumors	40
abstract_inverted_index.Patient	5
abstract_inverted_index.Filtered	28
abstract_inverted_index.analysis	24, 33, 48
abstract_inverted_index.mutation	14, 23, 32
abstract_inverted_index.Geometric	52
abstract_inverted_index.intensity	55
abstract_inverted_index.Unfiltered	19
abstract_inverted_index.sequencing	22, 31
abstract_inverted_index.information	9
abstract_inverted_index.fluorescence	54
abstract_inverted_index.Supplementary	2, 10, 16, 25, 34, 41, 49, 60
abstract_inverted_index.Representativeness	63
abstract_inverted_index.Immunohistochemistry	37
abstract_inverted_index.<p>Supplementary	0
abstract_inverted_index.Participants</p>	66
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	27
citation_normalized_percentile.value	0.33636313
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False